T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Novanta
NOVT
$6.39B
| $264M | 0.04% |
2,804,237
-30,230
| -1% | -$2.58M |
|
|
RTN
402
DELISTED
Raytheon Company
RTN
| $263M | 0.04% |
1,509,939
+212,361
| +16% | +$38.2M |
|
403
Sprouts Farmers Market
SFM
$7.96B
| $261M | 0.04% |
13,830,583
-52,317
| -0.4% | -$1.09M |
|
404
Domino's
DPZ
$11.7B
| $259M | 0.04% |
931,724
+300,755
| +48% | +$82.3M |
|
405
Lam Research
LRCX
$406B
| $258M | 0.04% |
13,734,850
-8,143,890
| -37% | -$155M |
|
406
Biogen
BIIB
$30.8B
| $257M | 0.04% |
1,097,770
+45,881
| +4% | +$10.6M |
|
407
Camden Property Trust
CPT
$10.9B
| $255M | 0.04% |
2,441,586
-168,687
| -6% | -$17.3M |
|
408
Alnylam Pharmaceuticals
ALNY
$29.9B
| $255M | 0.04% |
3,508,614
+25,025
| +0.7% | +$1.92M |
|
409
Aon
AON
$74.9B
| $254M | 0.04% |
1,317,652
+18,146
| +1% | +$3.29M |
|
410
Illumina
ILMN
$28.9B
| $254M | 0.04% |
708,984
-400,313
| -36% | -$126M |
|
411
SBA Communications
SBAC
$19.4B
| $253M | 0.04% |
1,127,228
-7,900
| -0.7% | -$1.67M |
|
412
Douglas Emmett
DEI
$1.95B
| $253M | 0.04% |
6,348,676
-811,113
| -11% | -$33.2M |
|
413
Regeneron Pharmaceuticals
REGN
$82.1B
| $252M | 0.04% |
804,402
-952,724
| -54% | -$317M |
|
|
ARRY
414
DELISTED
Array Biopharma Inc
ARRY
| $251M | 0.04% |
5,417,747
-8,002,987
| -60% | -$225M |
|
415
Uber
UBER
$154B
| $250M | 0.04% |
+5,646,316
| New | +$240M |
|
416
Ally Financial
ALLY
$13.4B
| $250M | 0.04% |
8,067,862
+1,096,715
| +16% | +$32.4M |
|
417
Okta
OKTA
$25.6B
| $248M | 0.03% |
2,005,180
-343,272
| -15% | -$37.3M |
|
418
Brink's
BCO
$4.71B
| $248M | 0.03% |
3,049,369
-197,951
| -6% | -$15.8M |
|
419
Tradeweb Markets
TW
$21.9B
| $246M | 0.03% |
+5,607,382
| New | +$234M |
|
420
Xencor
XNCR
$1.73B
| $246M | 0.03% |
6,000,960
-282,587
| -4% | -$9.28M |
|
421
Nucor
NUE
$62B
| $243M | 0.03% |
4,402,261
-181,780
| -4% | -$9.99M |
|
422
Liberty Broadband Class C
LBRDK
$5.1B
| $242M | 0.03% |
2,326,098
-85,983
| -4% | -$8.48M |
|
423
Landstar System
LSTR
$6.32B
| $241M | 0.03% |
2,228,045
-16,353
| -0.7% | -$1.74M |
|
424
Equitable Holdings
EQH
$14.2B
| $239M | 0.03% |
11,428,934
+1,819,129
| +19% | +$39.1M |
|
425
WIX.com
WIX
$2.88B
| $238M | 0.03% |
1,674,318
-628,289
| -27% | -$84.8M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.